Grifols Appoints New Senior Leadership Team
Grifols, a distinguished global healthcare company with a 115-year legacy as a leading manufacturer of plasma-derived medicines, has bolstered its senior management team through two strategic appointments. Dr. Roland Wandeler…
Staying Alert and Taking Precautions During Lunar New Year Celebrations Amidst Avian Influenza Concerns
Enhanced Precautions and Vigilance for Avian Influenza during Lunar New Year Celebrations in Asia As preparations for Lunar New Year festivities in Asia gain momentum, the increased trading and handling…
Rising Global Cancer Cases Highlight Increasing Demand for Healthcare Services
In anticipation of World Cancer Day, the International Agency for Research on Cancer (IARC), the cancer agency of the World Health Organization (WHO), has unveiled the latest global cancer burden…
Atara Biotherapeutics and Pierre Fabre Laboratories Release Phase 3 ALLELE Tab-cel® Results in The Lancet Oncology
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre…
ROHTO Pharmaceutical Forges Global Aesthetics Market Entry Through Long-Term Strategic and Equity Partnership with EMA Aesthetics
ROHTO Pharmaceutical Strengthens Global Presence with EMA Aesthetics Through Strategic Partnership EMA Aesthetics, a Dublin-based global aesthetics company, has announced a significant strategic and equity collaboration with ROHTO Pharmaceutical, a…
Vivet Therapeutics Secures EUR 4.9 Million to Progress Development of Gene Therapy Targeting Cerebrotendinous Xanthomatosis
Vivet Therapeutics Secures EUR 4.9 Million Government Funding for Gene Therapy Advancement in Cerebrotendinous Xanthomatosis Treatment” Vivet Therapeutics, a biotech company specializing in gene therapies for rare inherited metabolic disorders,…
Merck Inaugurates Its Maiden Digital Hub in Singapore
Merck Unveils First Digital Hub in Singapore, a Landmark Move Beyond the US and Europe In a strategic move, Merck, a leading science and technology company, has inaugurated its inaugural…
Newly Elected Board Members at E. Merck KG
E. Merck KG Announces Results of Board Election E. Merck KG, the entity holding approximately 70 percent of Merck KGaA on behalf of the Merck family, revealed the outcomes of…
Regeneron Establishes Regeneron Cell Medicines Through Acquisition of 2seventy Bio Platforms and Development Programs
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the establishment of Regeneron Cell Medicines, marking a strategic agreement with 2seventy bio, Inc. to acquire complete development and commercialization rights to its…
FDA Approves Kite’s Manufacturing Process Change, Leading to Faster Turnaround Time for Yescarta CAR T-cell Therapy
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene…
Gilead and Arcus Revise Collaboration Agreement and Equity Investment Terms
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced an amendment to their collaboration agreement, along with a separate equity investment by Gilead of $320 million…
Vertex Reports Favorable Outcomes from Phase 3 Trials of VX-548 for Managing Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has reported positive outcomes from its Phase 3 program for VX-548, a selective NaV1.8 inhibitor, designed to address moderate-to-severe acute pain. The Phase 3 program…